Your browser doesn't support javascript.
loading
In response to She et al., "Cost-effectiveness analysis of pembrolizumab versus chemotherapy as first-line treatment in locally advanced or metastatic non-small cell lung cancer with PD-L1 tumor proportion score 1% or greater".
Huang, Min; Insinga, Ralph P; Burke, Thomas; Zhang, Ying; de Lima Lopes, Gilberto.
Affiliation
  • Huang M; Center for Observational & Real World Evidence (CORE), Merck & Co., Inc., Kenilworth, NJ, 07033, USA. Electronic address: min_huang@merck.com.
  • Insinga RP; Center for Observational & Real World Evidence (CORE), Merck & Co., Inc., Kenilworth, NJ, 07033, USA.
  • Burke T; Center for Observational & Real World Evidence (CORE), Merck & Co., Inc., Kenilworth, NJ, 07033, USA.
  • Zhang Y; BARDS HTA Statistics Europe, MSD, 1200, Brussels, Belgium.
  • de Lima Lopes G; Sylvester Comprehensive Cancer Center, University of Miami & the Miller School of Medicine, Miami, FL, 33136, USA.
Lung Cancer ; 146: 385-386, 2020 08.
Article in En | MEDLINE | ID: mdl-32593484
Subject(s)
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Carcinoma, Non-Small-Cell Lung / Lung Neoplasms Type of study: Health_economic_evaluation Limits: Humans Language: En Journal: Lung Cancer Journal subject: NEOPLASIAS Year: 2020 Document type: Article Country of publication: Ireland
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Carcinoma, Non-Small-Cell Lung / Lung Neoplasms Type of study: Health_economic_evaluation Limits: Humans Language: En Journal: Lung Cancer Journal subject: NEOPLASIAS Year: 2020 Document type: Article Country of publication: Ireland